通心络胶囊联合尤瑞克林在急性脑梗死患者中应用效果

Application Effect of Tongxinluo Capsules Combined with Urinary Kallindinogenase in the Treatment of Patients with Acute Cerebral Infarction

目的:探究通心络胶囊联合尤瑞克林对急性脑梗死(ACI)患者神经功能和预后的影响。方法:选取2018年9月-2021年9月萍乡矿业集团有限责任公司总医院收治的160例ACI患者,按照随机数字表法将其分为对照组与观察组,各80例。对照组予以尤瑞克林静脉滴注治疗,观察组在对照组的基础上口服通心络胶囊。比较两组临床疗效、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、神经功能评定量表(NIHSS)、日常生活活动能力评定表(ADL)评分及不良反应。结果:观察组总有效率高于对照组(P<0.05)。治疗后,两组TC、TG、LDL-C水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(P<0.05)。随访3个月后,两组NIHSS评分均低于治疗前,ADL评分均高于治疗前,观察组NIHSS评分低于对照组,ADL评分高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:通心络胶囊联合尤瑞克林治疗急性脑梗死效果确切,能改善患者神经功能,利于患者预后,且有较高的安全性,值得临床推广应用。

Objective:To explore the effects of Tongxinluo Capsules combined with Urinary Kallindinogenase on nerve function and prognosis of patients with acute cerebral infarction(ACI).Method:A total of 160 patients with ACI admitted to General Hospital of Pingxiang Mining Group Co.,Ltd.from September 2018 to September 2021 were selected,according to random number table method,they were divided into control group and observation group,with 80 cases in each group.The control group was given intravenous drip of Urinary Kallindinogenase,while observation group was treated with Tongxinluo Capsules on the basis of control group.The clinical curative effect,total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C),scores of national institutes of health stroke scale(NIHSS)and activity of daily living scale(ADL)scores,adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of TC,TG and LDL-C of both groups were lower than those before treatment,and those of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After 3 months of follow-up,the NIHSS scores of both groups were lower than those before treatment,ADL scores of both groups were higher than those before treatment,and the NIHSS score of the observation group was lower than that of the control group,and the ADL score of the observation group was higher than that of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Tongxinluo Capsules combined with Urinary Kallindinogenase is effective in the treatment of acute cerebral infarction,which can improve the neurological function of patients,facilitate the prognosis of patients,and has high safety,which is worthy of clinical application.